Not specified
The FDA's Tentative Approval status for ANDA213093 indicates a significant step for QILU PHARM CO LTD, potentially enhancing their competitive positioning in the market. Monitoring the timeline for final approval is crucial for understanding market dynamics and preparing for competitive responses.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/31/2026, 6:32:29 PM
Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's Tentative Approval status for ANDA213093 indicates a significant step for QILU PHARM CO LTD, potentially enhancing their competitive positioning in the market. Monitoring the timeline for final approval is crucial for understanding market dynamics and preparing for competitive responses. Regulatory context from FDA (FDA AP — TOPIRAMATE (ORIG)) supports the near-term read. Assessment grounded in 18 ranked evidence items (6 high-relevance).
Portfolio teams should monitor the progress towards final approval and potential market entry strategies. The strongest clinical anchor is A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia (ClinicalTrials.gov), moderate corpus alignment. In Not specified, 6 regulatory and 3 competitive items passed relevance filtering for QILU PHARM CO LTD.
The most relevant competitive pressure comes from FDA Grants Priority Review for NUPLAZID Supplement NDA210793 (Humanexa Signals) — moderate corpus alignment. Secondary pressure from FDA grants priority review for NUPLAZID supplemental application. This tentative approval may position QILU PHARM CO LTD favorably in the market, pending final approval.
Regulatory risk is concentrated around FDA AP — TOPIRAMATE (ORIG) (FDA). Regulatory pathway relevance (nda). The tentative approval suggests that QILU is on a path towards potential market entry, but final approval is still pending, which carries regulatory risks.
FDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LAMOTRIGINE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA TA — CANAGLIFLOZIN (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceA Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePartial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceA Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Met
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Grants Priority Review for NUPLAZID Supplement NDA210793
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA grants priority review for NUPLAZID supplemental application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Development and in vivo pharmacokinetic evaluation of a phospholipid complex self-nanoemulsifying drug delivery system (PLC-SNEDDS) for enhanced oral bioavailability of cannabidiol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceSanguisorba officinalis L. polysaccharides: A review of structural characteristics, pharmacological activities, structure-activity relationships and applications.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceInvestigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's Tentative Approval status for ANDA213093 indicates a significant step for QILU PHARM CO LTD, potentially enhancing their competitive positioning in the market. Monitoring the timeline for final approval is crucial for understanding market dynamics and preparing for competitive responses.
If QILU secures final approval, it could capture market share and influence pricing strategies, impacting competitors' revenue streams.
The tentative approval suggests that QILU is on a path towards potential market entry, but final approval is still pending, which carries regulatory risks.
Follow-up on the timeline for final approval and any competitive responses from other companies in the same therapeutic area.
Track for follow-up milestones; no immediate action required.